Zidebactam is a diazabicyclooctane beta-lactamase inhibitor and PBP2-binding antibacterial, used only with cefepime, indicated for complicated urinary tract infections including pyelonephritis caused by susceptible Gram-negative pathogens. Zidebactam is a diazabicyclooctane that acts both as a beta-lactamase inhibitor and as an antibacterial in its own right, selectively binding penicillin-binding protein 2.
- Mechanism
- Curator reviewed
Pharmacologically active on Beta-lactamase, Peptidoglycan D,D-transpeptidase MrdA, and Carbapenem-hydrolyzing beta-lactamase KPC-2
- Primary indication
- Zidebactam in combination with cefepime is indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae...Curator reviewed · 2 structured indications
- Formula / weight
- C13H21N5O7S · 391.4 g/mol (avg)
- First approval
- United States, 2026
- Code names
- WCK-5107
- Brand names
Resolves to
YCZPXRQPDCXTIO-BBBLOLIVSA-NSMILESOS(=O)(=O)ON1[C@H]2C[N@]([C@@H](CC2)C(=O)NNC(=O)[C@@H]2CCCNC2)C1=OWhat you can answer from here — as of September 21, 2026
Which drugs share a target with Zidebactam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account